FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010476765> ?p ?o ?g. }

• W2010476765 endingPage "131" @default.
• W2010476765 startingPage "123" @default.
• W2010476765 abstract "SWOG trial S0102 showed significant activity of the combination of docetaxel and vinorelbine in HER2-negative metastatic breast cancer (MBC). For HER2-positive patients, additional benefit may occur with the addition of trastuzumab due to its synergy with docetaxel and vinorelbine. Patients with HER2-positive MBC, but without prior chemotherapy for MBC or adjuvant taxane, were eligible. Docetaxel (60 mg/m2) was given intravenously on Day 1, vinorelbine (27.5 mg/m2) intravenously on Days 8 and 15, and filgrastim (5 µg/kg) on Days 2–21 of a 21-day cycle. In addition, patients received weekly infusions of trastuzumab (2 mg/kg) after an initial bolus of 4 mg/kg. The primary outcome was 1 year overall survival (OS), with secondary outcomes of progression-free survival (PFS), response rate, and toxicity. Due to slow accrual (February 2003–December 2006), enrollment was stopped after 76 of 90 planned patients. There have been 32 deaths and 51 progressions among the 74 eligible patients who received treatment. The estimated 1 year OS was 93% (95% CI 84–97%) with a median of 48 months. One-year PFS was 70% (95% CI 58–79%) with a median of 20 months. Response rate for measurable disease was 84%. No deaths were attributed to treatment. Grade 4 toxicities were reported for 19% with neutropenia the most common (15%). The most common grade 3 toxicities (33%) were leucopenia (14%) and fatigue (10%). The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC with minimal toxicity. One-year survival estimates are among the highest reported in this population." @default.
• W2010476765 created "2016-06-24" @default.
• W2010476765 creator A5002818963 @default.
• W2010476765 creator A5008068115 @default.
• W2010476765 creator A5018617106 @default.
• W2010476765 creator A5025364402 @default.
• W2010476765 creator A5032585930 @default.
• W2010476765 creator A5050428554 @default.
• W2010476765 creator A5059538753 @default.
• W2010476765 creator A5069550177 @default.
• W2010476765 creator A5081974715 @default.
• W2010476765 date "2011-08-09" @default.
• W2010476765 modified "2023-09-23" @default.
• W2010476765 title "SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer" @default.
• W2010476765 cites W1823056587 @default.
• W2010476765 cites W1828283074 @default.
• W2010476765 cites W1976666735 @default.
• W2010476765 cites W1988737162 @default.
• W2010476765 cites W2016027388 @default.
• W2010476765 cites W2035332337 @default.
• W2010476765 cites W2035484878 @default.
• W2010476765 cites W2039387344 @default.
• W2010476765 cites W2044833729 @default.
• W2010476765 cites W2048686497 @default.
• W2010476765 cites W2050173898 @default.
• W2010476765 cites W2065767855 @default.
• W2010476765 cites W2106198994 @default.
• W2010476765 cites W2110444464 @default.
• W2010476765 cites W2114974083 @default.
• W2010476765 cites W2136791645 @default.
• W2010476765 cites W2143673928 @default.
• W2010476765 cites W2149773268 @default.
• W2010476765 cites W2158163505 @default.
• W2010476765 cites W2159305151 @default.
• W2010476765 cites W2165824128 @default.
• W2010476765 cites W2275704069 @default.
• W2010476765 cites W2318605753 @default.
• W2010476765 doi "https://doi.org/10.1007/s10549-011-1698-5" @default.
• W2010476765 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3513946" @default.
• W2010476765 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21826527" @default.
• W2010476765 hasPublicationYear "2011" @default.
• W2010476765 type Work @default.
• W2010476765 sameAs 2010476765 @default.
• W2010476765 citedByCount "6" @default.
• W2010476765 countsByYear W20104767652013 @default.
• W2010476765 countsByYear W20104767652014 @default.
• W2010476765 countsByYear W20104767652016 @default.
• W2010476765 countsByYear W20104767652021 @default.
• W2010476765 crossrefType "journal-article" @default.
• W2010476765 hasAuthorship W2010476765A5002818963 @default.
• W2010476765 hasAuthorship W2010476765A5008068115 @default.
• W2010476765 hasAuthorship W2010476765A5018617106 @default.
• W2010476765 hasAuthorship W2010476765A5025364402 @default.
• W2010476765 hasAuthorship W2010476765A5032585930 @default.
• W2010476765 hasAuthorship W2010476765A5050428554 @default.
• W2010476765 hasAuthorship W2010476765A5059538753 @default.
• W2010476765 hasAuthorship W2010476765A5069550177 @default.
• W2010476765 hasAuthorship W2010476765A5081974715 @default.
• W2010476765 hasBestOaLocation W20104767652 @default.
• W2010476765 hasConcept C121608353 @default.
• W2010476765 hasConcept C126322002 @default.
• W2010476765 hasConcept C143998085 @default.
• W2010476765 hasConcept C2775930923 @default.
• W2010476765 hasConcept C2776694085 @default.
• W2010476765 hasConcept C2777063308 @default.
• W2010476765 hasConcept C2777511904 @default.
• W2010476765 hasConcept C2778239845 @default.
• W2010476765 hasConcept C2779171977 @default.
• W2010476765 hasConcept C2779786085 @default.
• W2010476765 hasConcept C2780350996 @default.
• W2010476765 hasConcept C2781190966 @default.
• W2010476765 hasConcept C530470458 @default.
• W2010476765 hasConcept C71924100 @default.
• W2010476765 hasConceptScore W2010476765C121608353 @default.
• W2010476765 hasConceptScore W2010476765C126322002 @default.
• W2010476765 hasConceptScore W2010476765C143998085 @default.
• W2010476765 hasConceptScore W2010476765C2775930923 @default.
• W2010476765 hasConceptScore W2010476765C2776694085 @default.
• W2010476765 hasConceptScore W2010476765C2777063308 @default.
• W2010476765 hasConceptScore W2010476765C2777511904 @default.
• W2010476765 hasConceptScore W2010476765C2778239845 @default.
• W2010476765 hasConceptScore W2010476765C2779171977 @default.
• W2010476765 hasConceptScore W2010476765C2779786085 @default.
• W2010476765 hasConceptScore W2010476765C2780350996 @default.
• W2010476765 hasConceptScore W2010476765C2781190966 @default.
• W2010476765 hasConceptScore W2010476765C530470458 @default.
• W2010476765 hasConceptScore W2010476765C71924100 @default.
• W2010476765 hasIssue "1" @default.
• W2010476765 hasLocation W20104767651 @default.
• W2010476765 hasLocation W20104767652 @default.
• W2010476765 hasLocation W20104767653 @default.
• W2010476765 hasLocation W20104767654 @default.
• W2010476765 hasOpenAccess W2010476765 @default.
• W2010476765 hasPrimaryLocation W20104767651 @default.
• W2010476765 hasRelatedWork W1971716849 @default.
• W2010476765 hasRelatedWork W2010476765 @default.
• W2010476765 hasRelatedWork W2014205823 @default.
• W2010476765 hasRelatedWork W2016027388 @default.

• next